NRSN — Neurosense Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Neurosense Confirms Favorable Safety And Tolerability Of Primec In An Alzheimer's Phase 2 Study
Resuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis
U.S. STOCKS ON THE MOVE-Merck, Genco, Tesla
Brief: NeuroSense Receives FDA Clearance To Initiate Pivotal Phase 3 Trial For PrimeC In ALS
U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
NeuroSense rises after U.S. FDA clears late-stage ALS drug trial
Primec Produces Statistically Significant Reductions In Alzheimer’S Disease Biomarkers
Brief: Neurosense's Drug Candidate Shows Early Signals Of Benefit In Alzheimer's Patient-Derived Neurons
Neurosense Therapeutics Ltd expected to post a loss of 13 cents a share - Earnings Preview
Brief: Neurosense Therapeutics Announces Phase 2B Microrna Data
Brief: Neurosense Regains Compliance With Nasdaq's Minimum Equity Requirement
Neurosense Therapeutics Ltd reports results for the quarter ended September 30 - Earnings Summary
Brief: Neurosense Receives Positive FDA Feedback On Phase 3 Study Design For Primec
Brief: NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
Brief: Neurosense Therapeutics Files For Offering Of Up To 10 Million Ordinary Shares
Brief: Neurosense Secures Key FDA Meeting To Advance Its Phase 3 ALS Trial And NDA Submission
Neurosense Therapeutics Ltd expected to post a loss of 16 cents a share - Earnings Preview
Brief: NeuroSense Advances Plans For Early Commercialization Of Groundbreaking ALS Treatment In Canada, Provides Further Updates
Brief: Neurosense Therapeutics Plans To File For Early Commercialization Of ALS Treatment In Canada